Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?

Acta Neurologica Scandinavica

Volumn 111, Issue 6, 2005, Pages 353-359

  Papapetropoulos, S ^a   Lieberman, A ^a,b   Gonzalez, J ^a   Mash, D C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b National Parkinson Foundation   (United States)

Author keywords

Alzheimer's disease; Clinical phenotype; Neuropathology; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASPIRATION PNEUMONIA; BRAIN; CANCER; CONTROLLED STUDY; DEATH; DEPRESSION; DISEASE DURATION; FEMALE; HEART FAILURE; HUMAN; INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PARKINSON DISEASE; PHENOTYPE; PNEUMONIA; PSYCHOSIS; RESPIRATORY FAILURE; STROKE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CAUSALITY; COHORT STUDIES; COMORBIDITY; DEMENTIA; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PHENOTYPE; PSYCHOTIC DISORDERS;

EID: 18944367471     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00411.x     Document Type: Article

References (31)

1. BRAAK H, BRAAK E. Pathoanatomy of Parkinson's disease. J Neurol 2000;247(Suppl. 2):II3-10.
2. JELLINGER KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl 1997;51:57-82.
3. JENDROSKA K, LEES AJ, POEWE W, et al. Amyloid beta-peptide and the dementia of Parkinson's disease. Mov Disord 1996;116:647-53.
4. HUGHES AJ, DANIEL SE, KILFORD L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;553:181-4.
5. MCKEITH IG, GALASKO D, KOSAKA K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;475:1113-24.
6. American Psychiatric Association. Diagnostic and statistical manual for psychiatric disorders, revised 3rd edn. Washington, DC: American Psychiatric Association, 1987.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
8. FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 123:189-98.
9. LITVAN I, MACINTYRE A, GOETZ CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998;557:969-78.
10. MIRRA SS, HEYMAN A, MCKEEL D, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;414:479-86.
11. GIBB WR, LEES AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;516:745-52.
12. HUGHES AJ, DANIEL SE, BLANKSON S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;502:140-8.
13. JELLINGER KA, SEPPI K, WENNING GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;1093:329-39.
14. FENELON G, MAHIEUX F, HUON R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45.
15. HOLROYD S, CURRIE L, WOOTEN GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;706:734-8.
16. SANCHEZ-RAMOS JR, ORTOLL R, PAULSON GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;5312:1265-8.
17. AARSLAND D, LARSEN JP, CUMMINS JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;565:595-601.
18. MASTAGLIA FL, JOHNSEN RD, BYRNES ML, et al. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003;181:81-6.
19. JELLINGER KA. Prevalence of Alzheimer lesions in Parkinson's disease. Mov Disord 2003;1810:1207-8.
20. BOLLER F, MIZUTANI T, ROESSMANN U, et al. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980;74:329-35.
21. MANN DM, JONES D. Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome. Neurosci Lett 1990;1091/2:68-75.
22. QUINN NP, ROSSOR MN, MARSDEN CD. Dementia and Parkinson's disease - pathological and neurochemical considerations. Br Med Bull 1986;421:86-90.
23. APAYDIN H, AHLSKOG JE, PARISI JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;591:102-12.
24. MATTILA PM, RINNE JO, HELENIUS H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000;1003:285-90.
25. HURTIG HI, TROJANOWSKI JQ, GALVIN J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;5410:1916-21.
26. MATTILA PM, ROYTTA M, TORIKKA H, et al. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl) 1998;956:576-82.
27. VERMERSCH P, DELACOURTE A, JAVOY-AGID F, et al. Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal Tau proteins. Ann Neurol 1993;335:445-50.
28. LENNOX G. Dementia with Lewy bodies. In: Growdon JH, Rossor MN, eds. The dementias. Boston: Butterworth-Heinemann, 1998;67-80.
29. GOETZ CG, TANNER CM, KLAWANS HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;1394:494-7.
30. FACTOR SA, MOLHO ES, PODSKALNY GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-38.
31. HEITNER J, DICKSON D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 1997;495:1306-11.